Serena Williams' weight loss was aided GLP-1 medication for weight loss, losing 31 pounds. The tennis legend speaks on ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 ...

Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills ...

Serena Williams' revelation on Thursday that she'd lost 31 pounds came with another confession. Fans were angered with ...

The people of Northern Gaza are starving. That’s according to an official declaration by a United Nations-backed group of ...

In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Tennis star Serena Williams' candor about her GLP-1 use may help dispel the pesky health inaccuracy that weight loss is a ...

Serena Williams has revealed she lost 31 pounds on the GLP-1 Zepbound: "I just couldn't get my weight to where I needed to be at a healthy place." ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...